CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc. presented data that sets a new standard for EGFR-T790M resistance mutation detection in lung cancer, with the highest sensitivity reported ...
Exosome Diagnostics recently announced the launch of ExoDx Lung(ALK), a liquid biopsy platform that allows for non-invasive detection of biomarkers and potentially negates the need for a tissue biopsy ...
Earlier this year, Exosome Diagnostics said that it would scout out deals with biopharma partners to gain ground with its liquid biopsy tests. Now, the company is ...
Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore), or EPI, through FedMed, Inc., a ...
YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the ...
Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback